Tumor antigen-specific induction of transcriptionally targeted retroviral vectors from chimeric immune receptor-modified T cells

Nature Biotechnology

Volumn 20, Issue 3, 2002, Pages 256-263

  Chester, John ^a,b   Ruchatz, Anja ^a   Gough, Michael ^a   Crittenden, Marka ^a   Chong, Heung ^a   Loïc Cosset, François ^c   Diaz, Rosa Maria ^a   Harrington, Kevin ^a,d   Alvarez Vallina, Luis ^a,e   Vile, Richard ^a  

^a MAYO CLINIC   (United States)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^c CENTRE INTERNATIONAL DE RECHERCHE EN INFECTIOLOGIE   (France)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^e HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADHESION; ANTIGENS; CELLS; GROWTH KINETICS; IMMUNOLOGY; TUMORS;

IMMUNE NEUTRALIZATION;

BIOTECHNOLOGY;

GANCICLOVIR; RETROVIRUS VECTOR; TUMOR ANTIGEN; VIRUS VECTOR;

ADENOVIRUS; ARTICLE; CHIMERA; CONTROLLED STUDY; CYTOTOXICITY; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; LIVER METASTASIS; LUNG METASTASIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; T LYMPHOCYTE; TRANSCRIPTION REGULATION; TUMOR GROWTH; TUMOR LOCALIZATION; VIRUS INFECTION; VIRUS PARTICLE;

ADENOVIRIDAE; ANIMALS; CELL ADHESION; FLOW CYTOMETRY; GENE THERAPY; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HUMANS; JURKAT CELLS; LUMINESCENT PROTEINS; MICE; MICE, NUDE; MODELS, GENETIC; POLYMERASE CHAIN REACTION; PROTEIN STRUCTURE, TERTIARY; RETROVIRIDAE; T-LYMPHOCYTES; TIME FACTORS; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

ADENOVIRIDAE; UNIDENTIFIED RETROVIRUS;

EID: 0036200976     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/nbt0302-256     Document Type: Article

References (58)

1. Gene therapy - Promises, problems and prospects
2. Cancer gene therapy: Hard lessons and new courses
3. Modifying the host range properties of retroviral vectors
4. Combined targeting of adenoviruses to integrins and epidermal growth factor receptors increases gene transfer into primary glioma cells and spheroids
5. Genetic targeting of an adenovirus vector via replacement of the fiber protein with the phage T4 fibritin
6. Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism
7. Replication-selective virotherapy for cancer: Biological principles, risk management and future directions
8. Replicative adenoviruses for cancer therapy
9. Sensitization of cells and retroviruses to human serum by (α1-3) galactosyltransferase
10. Readministration of adenovirus vector in nonhuman primate lungs by blockade of CD40-CD40 ligand interactions
11. Circumventing adenovirus immune response to achieve long-term correction of genetic diseases
12. Initial binding of murine leukemia virus particles to cells does not require specific Env-receptor interaction
13. Blood clearance rates of adenovirus type 5 in mice
14. The macrophage - A novel system to deliver gene therapy to pathological hypoxia
15. Engineering of macrophages to produce IFN-γ in response to hypoxia
16. Generation of high-titer retroviral vector-producing macrophages as vehicles for in vivo gene transfer
17. Adoptive immunotherapy of cancer: Accomplishments and prospects
18. T cell recognition of human tumors: Implications for molecular immunotherapy of cancer
19. Tumor eradication by adoptive transfer of cytotoxic T lymphocytes
20. Monitoring of antigen-specific cytolytic T lymphocytes in cancer patients receiving immunotherapy
21. Melanocyte destruction after antigen-specific immunotherapy of melanoma: Direct evidence of T cell-mediated vitiligo
22. In vivo tracking of tumor-specific T cells
23. The intriguing role of polymorphonuclear neutrophils in antitumor reactions
24. The immunotherapy and gene therapy of cancer
25. + cells as cellular vehicles for gene delivery into areas of angiogenesis in a rhesus model
26. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization
27. Human tumor antigens recognized by T lymphocytes
28. Adoptive transfer of in vitro-targeted, activated T lymphocytes results in total tumor regression
29. Genetic re-targeting of T lymphocyte specificity
30. Redirecting the complete T cell receptor/CD 3 signaling machinery towards native antigen via modified T cell receptor
31. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the γ or ζ subunits of the immunoglobulin and T-cell receptors
32. A chimeric receptor that selectively targets membrane-bound carcinoembryonic antigen (mCEA) in the presence of soluble CEA
33. Single chain Ig/γ gene-redirected human T lymphocytes produce cytokines, specifically lyse tumor cells, and recycle lytic capacity
34. Pharmacological control of antigen responsiveness in genetically modified T lymphocytes
35. Pharmacologic suppression of target cell recognition by engineered T cells expressing chimeric T-cell receptors
36. Mapping of the inducible IκB phosphorylation sites that signal its ubiquitination and degradation
37. Expression and induction of nuclear factor-κB-related proteins in thymocytes
38. Protein kinase C and calcineurin synergize to activate IκB kinase and NF-κB in T lymphocytes
39. On the stochastic regulation of interleukin-2 transcription
40. Transcriptional regulation of the IL-2 gene
41. T cell antigen receptor signal transduction pathways
42. IκB interacts with the nuclear localization sequences of the subunits of NF-κB: A mechanism for cytoplasmic retention
43. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
44. Regulation of IκB α and p105 in monocytes and macrophages persistently infected with human immunodeficiency virus
45. Functional characterization of adenoviral/retroviral chimeric vectors and their use for efficient screening of retroviral producer cell lines
46. Advanced mammalian gene transfer: High titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line
47. Exchange of viral promoter/enhancer elements with heterologous regulatory sequences generates targeted hybrid long terminal repeat vectors for gene therapy of melanoma
48. A transcriptional feedback loop for tissue-specific expression of highly cytotoxic genes which incorporates an immunostimulatory component
49. Transcriptional regulatory sequences of carcinoembryonic antigen: Identification and use with cytosine deaminase for tumor-specific gene therapy
50. Nucleotide sequence of the thymidine kinase gene of herpes simplex virus type 1
51. Systemic gene therapy of murine melanoma using tissue-specific expression of the HSVtk gene involves an immune component
52. The "bystander effect": Tumor regression when a fraction of the tumor mass is genetically modified
53. Efficient discrimination between different densities of target antigen by tetracycline-regulatable T bodies
54. Impact of chimeric immune receptor extracellular protein domains on T cell function
55. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection
56. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors
57. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector
58. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo